Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
A few lines into the introduction they seem to dismiss any other system including microfluidic devices to isolate CTC clusters. When in fact Parsortix was instrumental in capturing and realising the negative effect on metastatic spread due to clusters.https://angleplc.com/angle-ctc-lab-services/enumeration-of-epithelial-and-mesenchymal-ctc-populations-including-ctc-clusters/
No one knows what is around the corner it could be a week it could be a year. As I say it's your call, but it's a risk/reward situation. By waiting the reward is probably 10p saving, the risk could quite easily be a loss £1 or more
It's because you bought at bang in the middle of the quotes. MMs don't report a trade as buy or sell, just a trade. LSE tries to guess
Bantam
I am perfectly happy with the route the company is taking
FL stated that unfortunately there are many steps for Angle to complete. I'm curious to know what these steps are
And to be honest I'm not that bothered with your opinion, someone who has no faith in the company or the board and not invested
FL
You say that it's unfortunate that Angle has a lot of steps to complete. Could you list them?
Don't just suggest that Angle has to expand its IP to include cancer types other than breast cancer, as we've already established that IP already exists
Parsortix is not limited to breast cancer. So to suggest that Angle need to broaden their IP to other cancer types is a tad unfair. I think to date it has been used successfully on 23 cancers,
https://angleplc.com/library/publications/
Abbott probably know a low ball offer would be rejected AN will not let this go cheap. That only leaves a hostile take over, of which the majority fail, especially if the target company has near term growth potential
FL
You are aware that Parsortix captures and allows retrieval of whole cancer cells not fragments of cells or ctDNA, so with that being said I can't se how it could be used to enhance the blood sample for a PCR based DNA amplification system. Unless I'm missing something.
One area I've often thought could be be a nice income is vetenary services. Everyone one I know with an aging dog has a problem with tumors. I'm not suggesting AGL get involved with selling or distribution. Find a licensee, Mr supervet for example. Give him an excluse license, let him do the donkey work. There are 29000 vets in the UK. If each vet used the service once per week, that would be £15m per anum for cassettes alone. Also realise that a dog develope a tumor from 7/8 years 8/9 X higher frequency than humans. I would guess regulation would be zero. A nice steady income so no more funding
One area I've often thought could be a nice steady income, is veterinary services. Nearly everyone I know with an aging dog have a problem with tumors at some point. I am not suggesting tha AGL invest any time in running it. They could find an influential licensee, Mr Supervet for example. Give him an exclusive license and leave him to do all the hard work. There are 29000 vets in the UK. If a vet used the service 1 per week that would be c £30,000,000 for cassettes alone per anum. I would regulation would be a breeze or zero. Also realise that you see tumors in dogs from 7 years on about 10 X the ratio of humans. Like I say pass all the donkey on to another company. Just box box shift the product. If nothing else it would avoid fund raising possibly